Farid Rashidi1,2, Rezayat Parvizi3, Eisa Bilejani3, Babak Mahmoodian4, Fatemeh Rahimi5, Ata Koohi6. 1. Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. fr2652@yahoo.com. 2. Tabriz University of Medical Sciences, Imam Reza General Hospital, 29 Bahaman St, Tabriz, Iran. fr2652@yahoo.com. 3. Cardiovascular Research Center, Tabriz University of Medical Sciences, Tabriz, Iran. 4. Medical Radiation Sciences Research Team, Tabriz University of Medical Sciences, Tabriz, Iran. 5. Department of Radiology, Imam Reza Teaching Center, Tabriz University of Medical Sciences, Tabriz, Iran. 6. Tuberculosis and Lung Diseases Research Center, Tabriz University of Medical Sciences, Tabriz, Iran.
Abstract
PURPOSE: Chronic thromboembolic pulmonary hypertension (CTEPH) is an important complication after acute pulmonary embolism (PE) with considerable morbidity and mortality. The aim of this study was to estimate the CTEPH incidence in a cohort after the first occurrence of PE. METHODS: We conducted a 1-year follow-up cohort study between 2015 and 2018 to assess the incidence of CTEPH in 474 patients with their first acute episode of PE. For the diagnosis of CTEPH, patients with unexplained persistent dyspnea during follow-up underwent transthoracic echocardiography, right heart catheterization, ventilation-perfusion lung scanning, and CT pulmonary angiography. RESULTS: Overall, 317 patients were included in the study. The mean age of the patients was 56.5 ± 16 years. One hundred and three patients (32%) had exertional dyspnea at the 1-year follow-up. Patients with evidence of pulmonary hypertension (PH) on echocardiography underwent right heart catheterization. Eleven patients (18%) had no PH (mPAP < 25 mmHg); 47 patients (81%) had mPAP > 25 mmHg. Fifteen patients had PAWP > 15 mmHg, including those with underlying left heart problems or valvular diseases. There were 32 patients with PAH (mPAP > 25 mmHg and PVR > 3 WU) undergoing CTEPH studies; 22 patients (6.9%) had multiple segmental defects suggesting CTEPH on a perfusion scan. CONCLUSION: The incidence of CTEPH observed in this study 1 year after the first episode of acute PE was approximately 6.9%. This incidence seems to be high in our population, and diagnostic and therapeutic strategies for the early identification of CTEPH are needed.
PURPOSE:Chronic thromboembolic pulmonary hypertension (CTEPH) is an important complication after acute pulmonary embolism (PE) with considerable morbidity and mortality. The aim of this study was to estimate the CTEPH incidence in a cohort after the first occurrence of PE. METHODS: We conducted a 1-year follow-up cohort study between 2015 and 2018 to assess the incidence of CTEPH in 474 patients with their first acute episode of PE. For the diagnosis of CTEPH, patients with unexplained persistent dyspnea during follow-up underwent transthoracic echocardiography, right heart catheterization, ventilation-perfusion lung scanning, and CT pulmonary angiography. RESULTS: Overall, 317 patients were included in the study. The mean age of the patients was 56.5 ± 16 years. One hundred and three patients (32%) had exertional dyspnea at the 1-year follow-up. Patients with evidence of pulmonary hypertension (PH) on echocardiography underwent right heart catheterization. Eleven patients (18%) had no PH (mPAP < 25 mmHg); 47 patients (81%) had mPAP > 25 mmHg. Fifteen patients had PAWP > 15 mmHg, including those with underlying left heart problems or valvular diseases. There were 32 patients with PAH (mPAP > 25 mmHg and PVR > 3 WU) undergoing CTEPH studies; 22 patients (6.9%) had multiple segmental defects suggesting CTEPH on a perfusion scan. CONCLUSION: The incidence of CTEPH observed in this study 1 year after the first episode of acute PE was approximately 6.9%. This incidence seems to be high in our population, and diagnostic and therapeutic strategies for the early identification of CTEPH are needed.
Authors: Nazzareno Galiè; Marc Humbert; Jean-Luc Vachiery; Simon Gibbs; Irene Lang; Adam Torbicki; Gérald Simonneau; Andrew Peacock; Anton Vonk Noordegraaf; Maurice Beghetti; Ardeschir Ghofrani; Miguel Angel Gomez Sanchez; Georg Hansmann; Walter Klepetko; Patrizio Lancellotti; Marco Matucci; Theresa McDonagh; Luc A Pierard; Pedro T Trindade; Maurizio Zompatori; Marius Hoeper Journal: Eur Respir J Date: 2015-08-29 Impact factor: 16.671
Authors: Diana Bonderman; Johannes Jakowitsch; Christopher Adlbrecht; Michael Schemper; Paul A Kyrle; Verena Schönauer; Markus Exner; Walter Klepetko; Meinhard P Kneussl; Gerald Maurer; Irene Lang Journal: Thromb Haemost Date: 2005-03 Impact factor: 5.249
Authors: Eckhard Mayer; David Jenkins; Jaroslav Lindner; Andrea D'Armini; Jaap Kloek; Bart Meyns; Lars Bo Ilkjaer; Walter Klepetko; Marion Delcroix; Irene Lang; Joanna Pepke-Zaba; Gerald Simonneau; Philippe Dartevelle Journal: J Thorac Cardiovasc Surg Date: 2011-03 Impact factor: 5.209
Authors: N Tanabe; A Kimura; S Amano; O Okada; Y Kasahara; K Tatsumi; M Takahashi; H Shibata; M Yasunami; T Kuriyama Journal: Eur Respir J Date: 2005-01 Impact factor: 16.671
Authors: Vittorio Pengo; Anthonie W A Lensing; Martin H Prins; Antonio Marchiori; Bruce L Davidson; Francesca Tiozzo; Paolo Albanese; Alessandra Biasiolo; Cinzia Pegoraro; Sabino Iliceto; Paolo Prandoni Journal: N Engl J Med Date: 2004-05-27 Impact factor: 91.245